The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Reagan Barnett
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - InVitro Cell Research
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Luciana Madeira da Silva
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Research Funding - Gradalis
Travel, Accommodations, Expenses - Guardant Health
 
May Thet Cho
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Eisai; Exelixis; Genentech/Roche; Ipsen; QED Therapeutics; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Helsinn Therapeutics; natera; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); incyte (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Merck (Inst)
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Incyte; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); Verastem (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Jonathan M. Loree
Consulting or Advisory Role - AMGEN; Bayer; Eisai; Ipsen; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Ipsen (Inst)
 
Sepideh Gholami
Consulting or Advisory Role - QED Therapeutics
Speakers' Bureau - Helsinn Therapeutics